PL3274710T3 - Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów - Google Patents

Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów

Info

Publication number
PL3274710T3
PL3274710T3 PL16716342T PL16716342T PL3274710T3 PL 3274710 T3 PL3274710 T3 PL 3274710T3 PL 16716342 T PL16716342 T PL 16716342T PL 16716342 T PL16716342 T PL 16716342T PL 3274710 T3 PL3274710 T3 PL 3274710T3
Authority
PL
Poland
Prior art keywords
cells
epithinal
rpe
potential
determination
Prior art date
Application number
PL16716342T
Other languages
English (en)
Inventor
Irina V. Klimanskaya
Julie Kathryn CARSON
Roger GAY
Yordanka Gikova IVANOVA
Original Assignee
Astellas Institute For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute For Regenerative Medicine filed Critical Astellas Institute For Regenerative Medicine
Publication of PL3274710T3 publication Critical patent/PL3274710T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL16716342T 2015-03-23 2016-03-23 Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów PL3274710T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136660P 2015-03-23 2015-03-23
PCT/US2016/023839 WO2016154357A1 (en) 2015-03-23 2016-03-23 Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
EP16716342.7A EP3274710B1 (en) 2015-03-23 2016-03-23 Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors

Publications (1)

Publication Number Publication Date
PL3274710T3 true PL3274710T3 (pl) 2021-12-27

Family

ID=55752717

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16716342T PL3274710T3 (pl) 2015-03-23 2016-03-23 Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów
PL21167900.6T PL3869195T3 (pl) 2015-03-23 2016-03-23 Ulepszone testy potencjału oddziaływania ludzkich komórek nabłonka barwnikowego siatkówki (RPE) i fotoreceptorów progenitorowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21167900.6T PL3869195T3 (pl) 2015-03-23 2016-03-23 Ulepszone testy potencjału oddziaływania ludzkich komórek nabłonka barwnikowego siatkówki (RPE) i fotoreceptorów progenitorowych

Country Status (16)

Country Link
US (3) US11422125B2 (pl)
EP (3) EP3274710B1 (pl)
JP (4) JP6902474B2 (pl)
KR (2) KR102577776B1 (pl)
CN (3) CN118995872A (pl)
AU (3) AU2016235176B2 (pl)
CA (2) CA3188112A1 (pl)
DK (1) DK3274710T3 (pl)
ES (2) ES2980659T3 (pl)
HU (1) HUE054946T2 (pl)
IL (3) IL293110B2 (pl)
MX (2) MX395233B (pl)
PL (2) PL3274710T3 (pl)
PT (2) PT3274710T (pl)
SG (3) SG10201907918VA (pl)
WO (1) WO2016154357A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011280878B2 (en) 2010-07-23 2016-06-16 Astellas Institute For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
ES2980659T3 (es) * 2015-03-23 2024-10-02 Astellas Inst For Regenerative Medicine Ensayos mejorados de potencia de células de epitelio pigmentario retiniano (EPR) humano y progenitores de fotorreceptores
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina
KR102452657B1 (ko) * 2020-09-09 2022-10-11 조선대학교 산학협력단 Noxa 단백질에서 유래한 펩타이드를 포함하는 세포외 소포 생산 촉진용 조성물 및 이를 이용한 세포외 소포의 생산 방법
DE102022103893A1 (de) * 2022-02-18 2023-08-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Membranvesikel, die einen spektroskopisch nachweisbaren Indikator beinhalten, und deren Verwendung in einem Verfahren zum Nachweis der Phagozytose-Funktion bei biologischen Zellen

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
EP1196426A4 (en) 1999-06-30 2003-09-03 Advanced Cell Tech Inc CYTOPLASMATIC TRANSFER FOR DE-DIFFERENTIATION OF VASCELL CELLS
US20040199935A1 (en) 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
EP1214443A4 (en) 1999-09-07 2003-08-27 Advanced Cell Tech Inc RESTORATION OF THE TELOMER AND EXTENSION OF THE CELL LIFETIME IN CLONED ANIMALS FROM SENESCENT SOMATIC CELLS
US20050255596A1 (en) 1999-09-07 2005-11-17 West Michael D Methods of repairing tandemly repeated DNA sequences and extending cell life-span nuclear transfer
US20040180430A1 (en) 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
IL149201A0 (en) 1999-11-02 2002-11-10 Univ Massachusetts Use of haploid genomes for genetic diagnosis, modification and multiplication
CA2394812A1 (en) 1999-12-20 2001-06-28 Anthony C.F. Perry A method to produce cloned embryos and adults from cultured cells
AU784731B2 (en) 1999-12-20 2006-06-08 University Of Massachusetts Embryonic or stem-like cells produced by cross species nuclear transplantation
AU2002258477A1 (en) 2001-03-08 2002-09-24 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
WO2002073188A1 (en) 2001-03-13 2002-09-19 Advanced Cell Technology, Inc. Method for generating replacement cells and/or tissues
JP2005500847A (ja) 2001-08-24 2005-01-13 アドバンスド セル テクノロジー、インコーポレイテッド 分化誘導薬の同定のためのスクリーニング検定及び細胞治療用の分化細胞の調製
AU2003300111A1 (en) 2002-12-27 2004-07-29 Advanced Cell Technology, Inc. Sperm-induced cellular activation
WO2005068610A1 (en) 2004-01-02 2005-07-28 Advanced Cell Technology, Inc. Novel culture systems for ex vivo development
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
AU2005207042B2 (en) 2004-01-23 2010-09-09 President And Fellows Of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
GB0407836D0 (en) 2004-04-06 2004-05-12 Univ Cambridge Tech Fluorescent dyes and complexes
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
EP2960328A1 (en) 2004-11-04 2015-12-30 Ocata Therapeutics, Inc. Derivation of embryonic stem cells
US20060263338A1 (en) 2005-03-04 2006-11-23 Jacoby Douglas B Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts
AU2006244197A1 (en) 2005-05-09 2006-11-16 Mytogen, Inc. Cellular cardiomyoplasty as supportive therapy in patients with heart disease
CA2659945C (en) 2005-08-03 2014-12-16 Advanced Cell Technology, Inc. Improved methods of reprogramming animal somatic cells
US20090271335A1 (en) 2005-10-20 2009-10-29 Advanced Cell Technology, Inc. Totipotent, Nearly Totipotent or Pluripotent Mammalian Cells Homozygous or Hemizygous for One or More Histocompatibility Antigent Genes
EP2029724A4 (en) 2006-05-03 2010-03-24 Advanced Cell Tech Inc DERIVATION FROM EMBRYONAL STEM CELLS AND EMBRYO-DERIVED CELLS
WO2008103462A2 (en) 2007-02-23 2008-08-28 Advanced Cell Technology, Inc. Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells
CN104946591A (zh) 2007-10-12 2015-09-30 奥卡塔治疗公司 制备rpe 细胞和rpe 细胞的组合物的改良方法
WO2009085212A1 (en) 2007-12-19 2009-07-09 Advanced Cell Technology, Inc. Methods for producing pluripotent stem cell-generated embryos, and animals derived therefrom
EP2501802A4 (en) 2009-11-17 2013-08-21 Advanced Cell Tech Inc METHOD FOR PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS FROM HUMAN RPE CELLS
AU2011280878B2 (en) 2010-07-23 2016-06-16 Astellas Institute For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20120184035A1 (en) 2011-01-13 2012-07-19 Sadhana Agarwal Methods and Compositions For Reprogramming Cells
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
RS57886B1 (sr) 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
CA3178138A1 (en) 2011-12-06 2013-06-13 Astellas Institute For Regenerative Medicine Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
US9511152B2 (en) 2012-04-05 2016-12-06 The Board Of Regents Of The University Of Texas System Multicolored pH-activatable fluorescence nanoplatform
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
KR102527507B1 (ko) 2013-03-15 2023-04-28 아스텔라스 인스티튜트 포 리제너러티브 메디슨 만능 줄기 세포로부터 제조된 광수용기 및 광수용기 전구체
JP6778181B2 (ja) 2014-09-05 2020-10-28 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜神経節細胞およびその前駆体
ES2980659T3 (es) 2015-03-23 2024-10-02 Astellas Inst For Regenerative Medicine Ensayos mejorados de potencia de células de epitelio pigmentario retiniano (EPR) humano y progenitores de fotorreceptores
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations

Also Published As

Publication number Publication date
EP3274710B1 (en) 2021-06-09
JP2021168655A (ja) 2021-10-28
IL293110B1 (en) 2023-07-01
EP3869195B1 (en) 2024-03-20
IL254617A0 (en) 2017-11-30
EP4343331A3 (en) 2024-06-19
IL303401A (en) 2023-08-01
KR102577776B1 (ko) 2023-09-11
EP3869195A1 (en) 2021-08-25
IL254617B (en) 2022-06-01
DK3274710T3 (da) 2021-09-06
SG10201912315UA (en) 2020-02-27
JP2024037720A (ja) 2024-03-19
MX2017012259A (es) 2018-05-17
HUE054946T2 (hu) 2021-10-28
ES2980659T3 (es) 2024-10-02
EP3274710A1 (en) 2018-01-31
SG10201907918VA (en) 2019-10-30
IL293110B2 (en) 2023-11-01
US20230051804A1 (en) 2023-02-16
JP7386206B2 (ja) 2023-11-24
US11422125B2 (en) 2022-08-23
US11680941B2 (en) 2023-06-20
MX395233B (es) 2025-03-25
AU2025226799A1 (en) 2025-11-06
CA3188112A1 (en) 2016-09-29
EP4343331A2 (en) 2024-03-27
AU2016235176B2 (en) 2022-05-19
MX2022010736A (es) 2022-09-23
US20180052150A1 (en) 2018-02-22
CN107889507A (zh) 2018-04-06
CN113930476B (zh) 2024-11-12
KR20180011761A (ko) 2018-02-02
PT3869195T (pt) 2024-06-17
JP2018516535A (ja) 2018-06-28
JP2025183199A (ja) 2025-12-16
US20230408489A1 (en) 2023-12-21
CA2980580C (en) 2024-01-23
AU2022218516A1 (en) 2022-09-08
AU2016235176A1 (en) 2017-10-26
PL3869195T3 (pl) 2024-07-22
SG11201707775TA (en) 2017-10-30
CN113930476A (zh) 2022-01-14
JP6902474B2 (ja) 2021-07-14
WO2016154357A1 (en) 2016-09-29
CA2980580A1 (en) 2016-09-29
PT3274710T (pt) 2021-07-06
CN118995872A (zh) 2024-11-22
KR20230132893A (ko) 2023-09-18
IL293110A (en) 2022-07-01
CN107889507B (zh) 2021-11-26
ES2877400T3 (es) 2021-11-16
AU2022218516B2 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
HRP20251095T1 (hr) Neoantigeni i metode njihove uporabe
IL256647A (en) Laboratory experiment data exploration and visualization
IL282048A (en) Oxysterols and methods of use thereof
IL271275A (en) Compositions comprising curons and uses thereof
IL260878B (en) Integrated interactive application security testing
IL254039A0 (en) Anti-pvrig antibodies and methods of use
HUE058755T2 (hu) Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
EP3471749A4 (en) METHOD AND COMPOSITIONS FOR DETECTING A TARGET RNA
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
MX384364B (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
PT3548033T (pt) Compostos e respectivos métodos de utilização
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
PT3148579T (pt) Anticorpos anti-gitr e métodos da sua utilização
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
EP3394065A4 (en) TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHOD OF USE THEREOF
BR112017004648A2 (pt) simuladores mir-29 e os usos deste
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EP3303435A4 (en) HYDROFLUOROLEFINES AND METHOD OF USE THEREOF